| Title |
Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases
|
|---|---|
| Published in |
Current Rheumatology Reports, November 2016
|
| DOI | 10.1007/s11926-016-0625-5 |
| Pubmed ID | |
| Authors |
Mary-Ann Fitzcharles, Winfried Häuser |
| Abstract |
The endocannabinoid system impacts pain and inflammation with potential for therapeutic effect on patients with rheumatic diseases. The current treatment options include the herbal product derived from the plant Cannabis sativa, as well as pharmaceutical preparations. The legalization of medicinal cannabis (marijuana) in many jurisdictions and widespread public advocacy has propelled an interest in use either by prescription or self-medication. In this review, we examine current evidence for efficacy and adverse effects of any cannabinoid product in rheumatic conditions. The evidence to date is scant and precludes making recommendations for the use of cannabinoid preparations in rheumatology patients. In particular, the risks of herbal cannabis in patients are not well defined. Anecdote and advocacy cannot supersede sound evidence. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 86 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 86 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 16% |
| Student > Ph. D. Student | 12 | 14% |
| Other | 10 | 12% |
| Student > Bachelor | 8 | 9% |
| Student > Master | 8 | 9% |
| Other | 19 | 22% |
| Unknown | 15 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 7% |
| Agricultural and Biological Sciences | 4 | 5% |
| Nursing and Health Professions | 3 | 3% |
| Engineering | 3 | 3% |
| Other | 20 | 23% |
| Unknown | 25 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 October 2017.
All research outputs
#2,833,127
of 23,857,313 outputs
Outputs from Current Rheumatology Reports
#100
of 727 outputs
Outputs of similar age
#48,365
of 315,931 outputs
Outputs of similar age from Current Rheumatology Reports
#1
of 9 outputs
Altmetric has tracked 23,857,313 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 727 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,931 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them